Skip to content

Study · Animal study (in vivo) · mouse · 2008

2 results

In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice.

Tolle V, Low MJ

Diabetes1 Oct 2007Cited by 67 (Europe PMC)

PMID17909095 (opens in a new tab)DOI10.2337/db07-0733 (opens in a new tab)PepBankPUB-17909095
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In hyperphagic POMC-deficient mice, intracerebroventricular MTII reduced food intake more than in wild-type mice.

    In plain wordsIn mice lacking POMC, melanotan II reduced eating more strongly than in normal mice.

    Peptide
    Melanotan II
    Outcome
    DecreaseAnorectic response to MTII
    Study

    mousen: not reported in source

    Neural-specific POMC-deficient and global POMC-deficient mice
    Comparator
    Wild-type mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Hyperphagic POMC-deficient mice were more sensitive than wild-type mice to the anorectic effects of MTII.
    1 context sentence
    Summary · context
    Feeding and metabolic effects of the MC-R agonist melanotan II (MTII), AgRP, and ghrelin were investigated after intracerebroventricular injection in neural-specific POMC-deficient (Pomc(-/-)Tg/+) and global POMC-deficient (Pomc(-/-)) mice.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In both POMC-deficient mouse strains, AgRP reversed the reduction in food intake that MTII caused.

    In plain wordsIn mice lacking POMC, the hormone AgRP reversed the eating reduction caused by melanotan II.

    Peptide
    Melanotan II
    Outcome
    IncreaseAgRP reversal of MTII-induced anorexia
    Study

    mousen: not reported in source

    Neural-specific POMC-deficient and global POMC-deficient mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    AgRP reversed MTII-induced anorexia in both mutant strains, demonstrating its ability to antagonize MSH agonists at central MC3/4-R, but did not produce an acute orexigenic response by itself.
    1 context sentence
    Summary · context
    Feeding and metabolic effects of the MC-R agonist melanotan II (MTII), AgRP, and ghrelin were investigated after intracerebroventricular injection in neural-specific POMC-deficient (Pomc(-/-)Tg/+) and global POMC-deficient (Pomc(-/-)) mice.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.